| Riboflavin Supplementation in Patients with Crohn’s Disease [the RISE-UP study] JZH von Martels, AR Bourgonje, MAY Klaassen, HAA Alkhalifah, ... Journal of Crohn's and Colitis 14 (5), 595-607, 2020 | 82 | 2020 |
| A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease AR Bourgonje, JZH Von Martels, RY Gabriëls, T Blokzijl, M Buist-Homan, ... Frontiers in medicine 6, 251, 2019 | 49 | 2019 |
| Serum free thiols are superior to fecal calprotectin in reflecting endoscopic disease activity in inflammatory bowel disease AR Bourgonje, RY Gabriëls, MH de Borst, MLC Bulthuis, KN Faber, ... Antioxidants 8 (9), 351, 2019 | 42 | 2019 |
| A comparative analysis of tioguanine versus low‐dose thiopurines combined with allopurinol in inflammatory bowel disease patients VBC Biemans, E Savelkoul, RY Gabriëls, M Simsek, G Dijkstra, MJ Pierik, ... Alimentary pharmacology & therapeutics 51 (11), 1076-1086, 2020 | 19 | 2020 |
| Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies JJH Van der Laan, AM Van der Waaij, RY Gabriëls, EAM Festen, ... Expert Review of Gastroenterology & Hepatology 15 (2), 115-126, 2021 | 13 | 2021 |
| Fitz-Hugh-Curtis syndrome resulting in nutmeg liver on computed tomography JP de Boer, IM Verpalen, RY Gabriëls, H de Haan, M Meijssen, ... Radiology Case Reports 14 (8), 930-933, 2019 | 8 | 2019 |
| Validation of novel molecular imaging targets identified by functional genomic mRNA profiling to detect dysplasia in Barrett’s esophagus X Zhao, RY Gabriëls, WTR Hooghiemstra, M Koller, GJ Meersma, ... Cancers 14 (10), 2462, 2022 | 4 | 2022 |
| Detection of early esophageal neoplastic Barrett lesions with quantified fluorescence molecular endoscopy using cetuximab-800CW RY Gabriëls, LE van Heijst, WTR Hooghiemstra, AM van der Waaij, ... Journal of Nuclear Medicine 64 (5), 803-808, 2023 | 3 | 2023 |
| In a Dutch real-life inflammatory bowel disease score cohort with 90% prior anti-tumour necrosis factor failure, vedolizumab showed a 25% remission rate: a retrospective … RY Gabriëls, APJ de Graaf, MAC Meijssen, JM Gotz, PBF Mensink, ... 11th Congress of European Crohn and Colitis Organization (ECCO), 2016 | 3 | 2016 |
| Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease RY Gabriëls, AR Bourgonje, JZH von Martels, T Blokzijl, RK Weersma, ... Journal of Clinical Medicine 11 (14), 4141, 2022 | 2 | 2022 |
| Today’s mistakes and tomorrow’s wisdom in endoscopic imaging of Barrett’s esophagus LE van Heijst, X Zhao, RY Gabriëls, WB Nagengast Visceral Medicine 38 (3), 182-188, 2022 | 2 | 2022 |
| Riboflavin suppresses inflammation and attenuates Crohn’s disease symptoms (RISE-UP Study) JZH von Martels, AR Bourgonje, MAY Klaassen, HAA Alkhalifah, ... Towards novel biomarkers and rational nutritional interventions in …, 2019 | 2 | 2019 |
| P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease RY Gabriëls, AR Bourgonje, J von Martels, T Blokzijl, R Weersma, ... Journal of Crohn's and Colitis 16 (Supplement_1), i517-i518, 2022 | 1 | 2022 |
| DOP15 Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during … RY Gabriels, M Linssen, A Van der Waaij, P Volkmer, W Hooghiemstra, ... Journal of Crohn's and Colitis 16 (Supplement_1), i064-i065, 2022 | 1 | 2022 |
| Id: 3525271 near-infrared fluorescence molecular endoscopy shows promising results in detecting dysplastic esophageal lesions using topically administered bevacizumab-800cw … RY Gabriëls, WT Hooghiemstra, I Schmidt, JJ van der Laan, ... Gastrointestinal Endoscopy 93 (6), AB289-AB290, 2021 | 1 | 2021 |
| ID: 3525469 Identification of dysplasia in the Barrett's esophagus using an endocytoscopy classification system: preliminary results of a prospective comparison between … JJ van der Laan, J Van Der Putten, X Zhao, I Schmidt, RY Gabriëls, ... Gastrointestinal Endoscopy 93 (6), AB206-AB207, 2021 | 1 | 2021 |
| Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease RY Gabriëls, AM van der Waaij, MD Linssen, M Dobosz, P Volkmer, ... Gut, 2024 | | 2024 |
| Detection and molecular analysis of inflammation and malignancies in the gastrointestinal tract: shining a new light on gastrointestinal diseases R Gabriëls | | 2024 |
| FLUORESCENTLY LABELLED VEDOLIZUMAB IDENTIFIED MACROSCOPIC AND MICROSCOPIC MUCOSAL DRUG DISTRIBUTION AND TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE R Gabriëls, A van der Waaij, M Linssen, P Volkmer, M Dobosz, ... Gastrointestinal Endoscopy 97 (6), AB550, 2023 | | 2023 |
| Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution and target cells in patients with inflammatory bowel disease AM van der Waaij, RY Gabriels, MD Linssen, P Volkmer, M Dobosz, ... Endoscopy 55 (S 02), OP135, 2023 | | 2023 |
